Trending NewsTrending NewsMost-Upgraded StocksMost-UpgradedNASDAQ:REGN Regeneron Pharmaceuticals (REGN) Stock Price, News & Analysis $959.41 +43.35 (+4.73%) Closing price 04:00 PM EasternExtended Trading$961.58 +2.18 (+0.23%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Regeneron Pharmaceuticals Stock (NASDAQ:REGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get REGN alerts:Sign Up Key Stats Today's Range$898.29▼$961.9850-Day Range$726.47▼$973.3652-Week Range$591.52▼$991.73Volume1.23 million shsAverage Volume945,677 shsMarket Capitalization$99.25 billionP/E Ratio19.18Dividend Yield0.39%Price Target$898.97Consensus RatingModerate Buy Company Overview Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations. Founded in 1988, Regeneron is headquartered in Tarrytown, New York. Co-founder Leonard S. Schleifer serves as president and chief executive officer, and co-founder George D. Yancopoulos is president and chief scientific officer.AI Generated. May Contain Errors. Read More Regeneron Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks78th Percentile Overall ScoreREGN MarketRank™: 3.91003007715 of 5 starsRegeneron Pharmaceuticals scored higher than 78% of companies evaluated by MarketBeat, and ranked 119th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingRegeneron Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.74, and is based on 1 strong buy rating, 21 buy ratings, 9 hold ratings, and no sell ratings.Downside RiskRegeneron Pharmaceuticals has a consensus price target of $898.97, representing about 6.3% downside from its current price of $959.41.Amount of Analyst CoverageRegeneron Pharmaceuticals has been the subject of 22 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Regeneron Pharmaceuticals' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth7.78% Earnings GrowthEarnings for Regeneron Pharmaceuticals are expected to grow by 7.78% in the coming year, from $58.26 to $62.79 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Regeneron Pharmaceuticals is 21.18, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.57.Price to Earnings Ratio vs. SectorThe P/E ratio of Regeneron Pharmaceuticals is 21.18, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 35.35.Price to Earnings Growth RatioRegeneron Pharmaceuticals has a PEG Ratio of 1.22. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRegeneron Pharmaceuticals has a P/B Ratio of 2.96. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Regeneron Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.30% of the float of Regeneron Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRegeneron Pharmaceuticals has a short interest ratio ("days to cover") of 2.73, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Regeneron Pharmaceuticals has recently increased by 3.85%, indicating that investor sentiment is decreasing. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldRegeneron Pharmaceuticals has a dividend yield of 0.41%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthRegeneron Pharmaceuticals does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Regeneron Pharmaceuticals is 8.30%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Regeneron Pharmaceuticals will have a dividend payout ratio of 5.99% next year. This indicates that Regeneron Pharmaceuticals will be able to sustain or increase its dividend.Read more about Regeneron Pharmaceuticals' dividend. News and Social Media4.2 / 5News Sentiment0.71 News SentimentRegeneron Pharmaceuticals has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 34 news articles for Regeneron Pharmaceuticals this week, compared to 9 articles on an average week.Search Interest14 people have searched for REGN on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.MarketBeat Follows13 people have added Regeneron Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 86% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Regeneron Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $25,025,950.00 in company stock.Percentage Held by Insiders6.97% of the stock of Regeneron Pharmaceuticals is held by insiders.Percentage Held by Institutions83.31% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Regeneron Pharmaceuticals' insider trading history. Receive REGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. REGN Stock News HeadlinesRegeneron Pharmaceuticals, Inc. (REGN) Discusses Genetic Center and CIDEB siRNA Development for MASH TranscriptNovember 10 at 4:01 PM | seekingalpha.comAmgen vs. Regeneron: Higher Dividends Now or Bigger Growth Later?November 10 at 1:17 PM | 247wallst.comMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.November 11 at 1:00 AM | Weiss Ratings (Ad)3 Biotech Stocks That Actually Pay Dividends and Keep Raising ThemNovember 10 at 12:43 PM | 247wallst.comAlnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLDNovember 10 at 12:43 PM | finance.yahoo.comInsider Selling: Regeneron Pharmaceuticals (NASDAQ:REGN) Director Sells 7,439 Shares of StockNovember 6, 2026 | insidertrades.comInsider Selling: Regeneron Pharmaceuticals (NASDAQ:REGN) EVP Sells $4,311,878.34 in StockNovember 5, 2026 | insidertrades.comRegeneron Pharmaceuticals (NASDAQ:REGN) Director Kathryn Guarini Sells 400 Shares of Company StockNovember 4, 2026 | insidertrades.comSee More Headlines REGN Stock Analysis - Frequently Asked Questions How have REGN shares performed this year? Regeneron Pharmaceuticals' stock was trading at $771.87 on January 1st, 2026. Since then, REGN shares have increased by 24.3% and is now trading at $959.41. How were Regeneron Pharmaceuticals' earnings last quarter? Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) posted its quarterly earnings results on Friday, October, 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $16.51 by $3.56. The company's quarterly revenue was up 36.3% on a year-over-year basis. Read the conference call transcript. Does Regeneron Pharmaceuticals have any subsidiaries? The following companies are subsidiaries of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, Old Saw Mill Holdings LLC, OSMR Holdings, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, and others. Who are Regeneron Pharmaceuticals' major shareholders? Regeneron Pharmaceuticals' top institutional investors include Aberdeen Group plc (0.65%), Robeco Institutional Asset Management B.V. (0.39%), Sumitomo Mitsui Trust Group Inc. (0.27%) and Russell Investments Group Ltd. (0.20%). Insiders that own company stock include George Yancopoulos, Leonard S Schleifer, Andrew J Murphy, Joseph J Larosa, Arthur F Ryan, Christopher R Fenimore, Marion Mccourt, Joseph L Goldstein, Christine A Poon, Jason Pitofsky, Huda Y Zoghbi, Bonnie L Bassler, Michael S Brown and Kathryn Guarini. View institutional ownership trends. How do I buy shares of Regeneron Pharmaceuticals? Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Regeneron Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Micron Technology (MU), Alibaba Group (BABA) and Gilead Sciences (GILD). Company Calendar Record date for 8/31 Dividend8/18/2026Ex-Dividend for 8/31 Dividend8/18/2026Dividend Payable8/31/2026Last Earnings10/30/2026Today11/11/2026Jefferies Global Healthcare Conference11/17/2026Record date for 12/3 Dividend11/20/2026Ex-Dividend for 12/3 Dividend11/20/20269th Annual Evercore ISI HealthCONx Conference12/01/2026Citi Annual Global Healthcare Conference 202612/02/2026Dividend Payable12/03/2026Fiscal Year End12/31/2026Next Earnings (Estimated)1/28/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 REGN's financial health is in the Green zone, according to TradeSmith. REGN has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:REGN CIK872589 Webwww.regeneron.com Phone(914) 847-7000Fax914-347-2113Employees15,410Year Founded1988Price Target and Rating Average Price Target for Regeneron Pharmaceuticals$898.97 High Price Target$1,100.00 Low Price Target$185.00 Potential Upside/Downside-6.3%Consensus RatingModerate Buy Rating Score (0-4)2.74 Research Coverage31 Analysts Profitability EPS (Trailing Twelve Months)$45.29 Trailing P/E Ratio21.18 Forward P/E Ratio15.28 P/E Growth1.22Net Income$4.50 billion Net Margins28.51% Pretax Margin33.66% Return on Equity16.01% Return on Assets12.22% Debt Debt-to-Equity Ratio0.06 Current Ratio3.35 Quick Ratio2.89 Sales & Book Value Annual Sales$14.34 billion Price / Sales6.92 Cash Flow$43.77 per share Price / Cash Flow21.92 Book Value$323.82 per share Price / Book2.96Miscellaneous Outstanding Shares103,450,000Free Float96,238,000Market Cap$99.25 billion OptionableOptionable Beta0.10 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:REGN) was last updated on 11/11/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regeneron Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
